CHDI’s goal is to increase the understanding of Huntington’s disease (HD) and to hasten the development of therapies.We collaborate with academic and industrial scientists throughout the world.

This website highlights activities that may be of particular interest to people engaged in or contemplating HD research and provides information on targets, compounds, and research materials that HD researchers may find useful.

Please join our mailing list

News Headlines

  • 10/13/2009

    Dotmatics has Licensed its Browser and Vortex solutions to CHDI

    Dotmatics Limited (Dotmatics), a leading provider of drug discovery informatics products and services, is pleased to announce they have been selected by CHDI Foundation, Inc. to provide scientific data management, data mining, and analysis solutions.

  • 04/29/2009

    AMRI Commences Drug Discovery Collaboration

    AMRI (NASDAQ: AMRI) and CHDI Foundation, Inc., a non-profit organization pursuing drugs that delay or slow Huntington’s disease (HD), announced today the commencement of a new collaboration agreement focused on the discovery of new therapeutic agents for the treatment of this disease.

Upcoming Events